Health and Healthcare
AbbVie, Cigna and Other Health Care Stocks With Recent Golden Crosses
Published:
Last Updated:
Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages. The golden cross typically is seen as a bullish sign, perhaps a stock that has broken out or is about to. The death cross, on the other hand, can be a bearish sign, perhaps warning investors to get out of the way or signaling that it may be time short the stock.
Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.
[in-text-ad]
AbbVie Inc. (NYSE: ABBV) saw its golden cross about a week ago, the first in more than two years. This remains a popular baby boomer retirement stock pick. Shares climbed about 16% in the past month, though they are trading in the same neighborhood as at the beginning of the year. Analysts on average recommend buying shares.
Agile Therapeutics Inc.’s (NASDAQ: AGRX) short-term moving average crossed above the long-term one last week, reversing the death cross seen in late September. The stock surged after a positive FDA reaction to the company’s Twirla contraceptive patch. Despite pulling back some late last week, the shares are still up more than 25% in the past month, while the S&P 500 has gained less than 5% in that time. Analysts overall recommend buying shares.
The rise in the Cardinal Health Inc. (NYSE: CAH) short-term moving average began in earnest in mid-October, and the gap between the two moving averages is up to almost 3% of the share price. Earlier this month, Cardinal Health agreed to pay more than $5 million related to opioid crisis claims. Shares are up about 9% from this time a month ago. Still, the consensus recommendation is to hold shares and has been for months.
Cigna Corp. (NYSE: CI) saw a golden cross last week as well. The long-term average dropped below the other back in February. The stock has seen some analysts raise their price targets recently, and it is a top Merrill Lynch pick for 2020. Shares are currently up more than 17% in the past 30 days, and most of the analysts surveyed recommend buying shares.
Immunomedics Inc.’s (NASDAQ: IMMU) golden cross happened earlier this month, and the difference in the two averages is up to about 46 cents, or more than 2% of the share price, so far. The company posted a larger than expected third-quarter net loss late last month. Yet, its shares are up more than 13% in the past month and about 17% year to date. The consensus recommendation (of only three analysts) is to buy the shares.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.